

Regd. & Corp. Office:
1506, Chiranjiv Tower,
43, Nehru Place,
New Delhi - 110019 (INDIA)

Tel.: 011 - 47589500-51 (50 Lines),
E-mail: info@medicamen.com
Web: www.medicamen.com
CIN No.: L74899DL1993PLC056594

Ref: STEX/Results/Published-2019-20

Date: 11th November, 2019

The BSE Ltd.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400001

Company Number: 531146

Sub. : Copy of Publication of Un-audited Financial Results for the Quarter and Half Year ended on 30th September, 2019

Dear Sir,



Pursuant to Regulation 47 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the copies of newspaper publication pertaining to the Un-audited Financial Results for the Quarter and Half Year ended on 30th September, 2019, published in Financial Express (English) and Jansatta (Hindi) newspaper on 09.11.2019.

This is for your information and records.

Kindly acknowledge the receipt.

Thanking You,

Yours truly,
For Medicamen Biotech Limited



Parul Choudhary
Company Secretary

Encl: As above.

6.	Equity Share Capital (Face value ₹10/- each)	668.75
7.	Earnings Per Share (of ₹10/- each)	
	1. Basic (in ₹)	1.86
	2. Diluted (in ₹)	1.86

Note : The above is an extract of the detailed format of Stock Exchange under Regulation 33 of the SEBI (Listing) Regulations, 2015. The full format of the unaudited Quarterly Financial Results for the quarter and half year ended on 30.09.2019 is available on the website of the Company (www.bseindia.com) and the website of the Company (www.salautomotive.com).

Coimbatore
08.11.2019

SAL AUTOMOTIVE

(formerly Swaraj)
CIN : L45202P

Regd. Office : C-127, IV Floor
Industrial Area, S.A.S. Nagar
Tel : 0172-465037

Email : kaushik.gagan@salautomotive.com

EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR

Sl. No.	Particulars
1.	Total Income from Operations (Gross)
2.	Total Income from Operations (Net)
3.	EBDITA
4.	Net Profit/(Loss) (before tax, exceptional and extraordinary items)
5.	Net Profit/(Loss) (before tax, after exceptional and extraordinary items)
6.	Tax Expense
7.	Net Profit/(Loss) (after tax, exceptional and extraordinary items)
8.	Total Comprehensive Income (comprising profit/(loss) after tax and other comprehensive income after tax)
9.	Paid-up Equity Share Capital (Face Value ₹10/-)
10.	Reserves (excluding Revaluation Reserve)
11.	Earning Per Share on net profit after tax (Not Annualised)
	- Basic
	- Diluted

Notes:

- The above is an extract of the detailed format of Financial Results (as per the Companies Act, 2013 and the Companies (Disclosure Requirements) Regulations, 2015) available on the website of the Company (www.bseindia.com) and on the Company Website (www.salautomotive.com).
- The above financial results were reviewed by the audit committee of the Company on 7th Nov, 2019. The Statutory Auditors have concluded their audit report on 7th Nov, 2019.
- These financial results have been prepared in accordance with the "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 and other accounting principles relevant thereto.
- Net Profit/(Loss) after tax, exceptional and extraordinary items for the period ending on 30th September, 2019 includes profit of ₹ 223 lakhs (net of tax).
- As per Ind AS - 108 dealing with "Operating Segment", the Company's operating segments are:
 - Automobile Components, which includes Tractors, Jeeps, Commercial vehicles;
 - Agriculture Implements, which includes Rotavators, Tractors

Place: Ghaziabad
Date : 7th Nov, 2019

Re
Fax:
STATEMENT OF FINANCIAL RESULTS FOR



MEDICAMEN BIOTECH LTD.

Regd. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi- 110019
(CIN: L74899DL1993PLC056594) Website: www.medicamen.com
Email id: cs@medicamen.com

Extracts of Un-Audited standalone Financial Results for the Quarter and Half Year ended on 30.09.2019 (In Lakhs)

Sl. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		Un-Audited 30.09.2019	Un-Audited 30.06.2019	Un-Audited 30.09.2018	Un-Audited 30.09.2019	Un-Audited 30.09.2018	Audited 31.03.2019
1	Total income from operations (net)	3,586.81	3,116.75	3,429.36	6,703.56	6,821.99	12,626.32
2	Net Profit/ (Loss) for the period (before tax, exceptional and/ or Extraordinary items)	521.93	431.77	510.97	953.70	964.96	1,752.28
3	Net Profit/ (Loss) for the period before tax (after exceptional and/or Extraordinary items)	521.93	431.77	510.97	953.70	964.96	1,752.28
4	Net Profit/ (Loss) for the period after tax (after exceptional and/ or Extraordinary items)	383.72	328.13	355.98	711.85	678.18	1,202.58
5	Total comprehensive income for the period (Comprising Profit/(loss) for the period (after tax) and other Comprehensive income (after tax))	383.72	328.13	355.98	711.85	678.18	1,202.58
6	Equity Share Capital	1,221.66	1,221.66	1,170.00	1,221.60	1,170.00	1,170.00
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)						7,493.36
8	Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operation)						
	Basic:	3.18	2.75	3.05	5.89	5.80	10.28
	Diluted:	3.18	2.75	3.05	5.89	5.80	10.28

Note:

- The above results after being reviewed by the Audit Committee have been taken on record by the Board at its Meeting held on 08th November, 2019.
- The statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- The Company has acquired controlling stake of OPAL Pharmaceuticals Pty Ltd (a company incorporated in Australia) from its existing shareholder which is a marketing and trading company of Pharmaceuticals products.
- Pharma Oncology plant at Haridwar shall be operational by Dec, 2019.
- The Company operates only in one segment, viz Pharmaceuticals formulations, hence segment reporting is not applicable.
- The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33-"Earning Per Share"
- Limited Review Report has been carried out by the Statutory Auditors for the above period.
- The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.

For Medicamen Biotech Limited
Sd/-
Rahul Bishnoi
Chairman

Place: New Delhi
Date : 08.11.2019

MUTUAL FUNDS

Sahi Hai



Haq, ek behtar zindagi ka.

NOTICE - CUM - ADDENDUM

Change in Benchmark Indices - UTI Equity Fund, UTI Value Opportunities Fund, UTI Long Term Equity Fund (Tax Saving) & UTI Children's Career Fund - Investment Plan

The benchmark Indices of the following schemes of UTI Mutual Fund are being revised as under with effect from November 11, 2019:

Name of the Scheme	Existing Benchmark	Revised Benchmark
UTI Equity Fund		
UTI Value Opportunities Fund		
UTI Long Term Equity Fund (Tax Saving)	S&P BSE 200	Nifty 500

PARAMOUNT CABLES

ULTS

(₹ in Lakhs)

LIDATED		
Six month Ended		Year Ended
30.09.2019	30.09.2018	31.03.2019
Unaudited	Unreviewed	Audited
30,678.03	26,063.46	61,446.33
1,389.47	1,066.70	2,915.96
1,389.47	1,066.70	2,915.96
1,389.47	1,066.70	2,915.96
0.43	(2.75)	0.86
1,389.90	1,063.95	2,916.82
3,435.68	3,435.68	3,435.68
-	-	10,706.21
0.81	0.65	1.74
0.81	0.65	1.74

ations 33 of the SEBI (Listing Obligations and
change's websites, www.nseindia.com and

By and on behalf of the Board
PARAMOUNT COMMUNICATIONS LTD.
Sd/-
Sanjay Aggarwal
(Chairman & CEO)
DIN: 00001788



ed.co.in

(₹ करोड़ में)

समेकित	2019 को त्रैमासिक (अप्रैरिक्त)	30.09.2018 को समाप्त त्रैमासिक (अलेखापरीक्षित)	31.03.2019 को समाप्त वर्ष (लेखापरीक्षित)
17.30	6,570.50	8,903.44	
3.40	(11.62)	(184.57)	
11.11	(11.73)	(899.06)	
11.11	(12.63)	(883.02)	
11.11	(12.63)	(881.40)	
0.00	60.00	60.00	
60.33	(4,590.45)	(5,459.22)	
6.85	(2.11)	(147.17)	
6.85	(2.11)	(147.17)	

मन सिद्धांतों के अनुसार तैयार किया गया है।
ते का प्रस्ताव दिया है और तदनुसार मुगतान के भाग के
र इसका पुरजोर फालोअप किया जा रहा है।
के यदि परिस्थितिवश राशि की बसूली नहीं भी होती है तो
न एंड डीओ/एलएस2ए/9225/133 के तहत पत्रा विलेख
त पर किया जाएगा। तथापि एसटीसी ने मांग पर विवाद
नहीं हुआ है इस प्रकार उक्त मांग हेतु स्पष्ट देयता का पता
का गया था। एल एंड डीओ से यह भी अनुबंध किया गया
व रूप से विभिन्न देशों के राज्य व्यापार संगठनों के साथ
की व्यापार गतिविधियों को करने हेतु आवश्यक मूलभूत
नके साथ कंपनी ने व्यापार लेनदेन किये थे और जिन्होंने
नीय सर्वोच्च न्यायालय के निर्देश पर एसटीसी को पर्याप्त
के मद्देनजर ऐसा माना जाता है कि प्रस्तावित समझौते के
या है। ऐसा विश्वास है कि यह एसटीसी के लिए पुनर्खर्च
है और ऊपर दिए गए तथ्यों पर विचार करते हुए-



MEDICAMEN BIOTECH LTD.

Regd. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi- 110019
(CIN: L74899DL1993PLC056594) Website: www.medicamen.com
Email id: cs@medicamen.com

Extracts of Un-Audited standalone Financial Results for the Quarter and Half Year ended on 30.09.2019

(In Lakhs)

Sl. No.	Particulars	Quarter Ended			Half Year-Ended		Year Ended
		Un-Audited 30.09.2019	Un-Audited 30.06.2019	Un-Audited 30.09.2018	Un-Audited 30.09.2019	Un-Audited 30.09.2018	Audited 31.03.2019
1	Total income from operations (net)	3,586.81	3,116.75	3,429.36	6,703.56	6,821.99	12,626.32
2	Net Profit/ (Loss) for the period (before tax, exceptional and/ or Extraordinary items)	521.93	431.77	510.97	953.70	964.96	1,752.28
3	Net Profit/ (Loss) for the period before tax (after exceptional and/or Extraordinary items)	521.93	431.77	510.97	953.70	964.96	1,752.28
4	Net Profit/ (Loss) for the period after tax (after exceptional and/ or Extraordinary items)	383.72	328.13	355.98	711.85	678.18	1,202.58
5	Total comprehensive income for the period (Comprising Profit/(loss) for the period (after tax) and other Comprehensive income (after tax))	383.72	328.13	355.98	711.85	678.18	1,202.58
6	Equity Share Capital	1,221.66	1,221.66	1,170.00	1,221.60	1,170.00	1,170.00
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)						7,493.36
8	Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operation)						
	Basic:	3.18	2.75	3.05	5.89	5.80	10.28
	Diluted:	3.18	2.75	3.05	5.89	5.80	10.28

Note:

- The above results after being reviewed by the Audit Committee have been taken on record by the Board at its Meeting held on 08th November, 2019.
- The statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- The Company has acquired controlling stake of OPAL Pharmaceuticals Pty Ltd (a company incorporated in Australia) from its existing shareholder which is a marketing and trading company of Pharmaceuticals products.
- Pharma Oncology plant at Haridwar shall be operational by Dec, 2019.
- The Company operates only in one segment, viz Pharmaceuticals formulations, hence segment reporting is not applicable.
- The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33-"Earning Per Share"
- Limited Review Report has been carried out by the Statutory Auditors for the above period.
- The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.

For Medicamen Biotech Limited
Sd/-
Rahul Bishnoi
Chairman

Place: New Delhi
Date : 08.11.2019

VANI COMMERCIALS LIMITED

Regd. Off.: 'AASTHA', LP -11C, Pitampura, New Delhi - 110034
CIN: L74899DL1988PLC106425, Ph: 011-27324080

Website: www.vanicommercials.com, Email ID: info@vanicommercials.com

EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER, 2019 (₹. in Lakh)

Sl. No.	Particulars	3 Months ended 30.09.2019	Preceding 3 Months ended 30.06.2019	Corresponding 3 Months ended (Previous Year) 30.09.2018	Year to date (Current Year)(6 months) 30.09.2019	Year to date (Previous Year) 30.09.2018	Previous Year Ended 31.03.2019
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Total Income from Operations	13,916	9,435	7,220	23,351	13,297	26,063
2	Net Profit/ (Loss) for the period (before tax and Exceptional Items)	0,319	0,484	0,649	0,803	0,795	2,351
3	Net Profit/ (Loss) for the period before tax (after Exceptional Items)	0,319	0,484	0,649	0,803	0,795	2,351
4	Net Profit/ (Loss) for the period after tax (after Exceptional Items)	0,319	0,484	0,649	0,803	0,795	1,117
5	Total Comprehensive Income for the period, (Comprising Profit/ (Loss) for the period (after tax) and Other Comprehensive Income (after tax))	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.
6	Equity Share Capital	411,980	411,980	411,980	411,980	411,980	411,980
7	Reserves (excluding Revaluation Reserve)	0,000	0,000	0,000	0,000	0,000	3,449
8	Earnings Per Share (of ₹10/- each):						
	1. Basic (₹):	0.00	0.01	0.00	0.00	0.00	0.00
	2. Diluted (₹):	0.00	0.00	0.00	0.00	0.00	0.00

Note:

a) The above is an extract of the detailed format of the Statement of Unaudited Financial Results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing